专利检索 ap:("SmithKline Beecham plc" OR "Laboratoire GlaxoSmithKline S.A.S.") AND inv:"BUCKINGHAM, Robin, Edwin" 第 1 页

1.

发明授权
USE OF THE GLUCOSE UPTAKE ENHANCER ROSIGLITAZONE FOR REDUCING ISCHAEMIA-INDUCED APOPTOSIS OF PANCREATIC BETA CELLS, ENDOTHELIAL CELLS AND NEURONAL CELLS 有权
标题翻译：使用放大器葡萄糖RECORD罗格列酮，以减少缺血诱导的凋亡内皮细胞和神经细胞的胰腺β细胞

公开(公告)号：EP1098639B1

公开(公告)日：2005-02-09

申请号：EP99934914.5

申请日：1999-07-21

申请人： SmithKline Beecham plc , Laboratoire GlaxoSmithKline S.A.S.

发明人： BRIL, Antoine, M. A. , BUCKINGHAM, Robin, Edwin , KHANDOUDI, Nassirah

IPC分类号： A61K31/00 , A61K31/425 , A61K31/44 , A61P9/10

CPC分类号： A61K31/00

摘要： A method for reducing or preventing apoptosis of differentiated cells selected from the list consisting of cardiac myocytes, pancreatic beta cells, endothelial cells and neuronal cells in the human or non-human mammal, which method comprises administration, including acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.